MaherJ.F.Pharmacologic considerations for renal failure and dialysis. In: MaherJ.F.. Replacement of renal function by dialysis.3rd ed.Dordrecht: Kluwer Academic, 1989: 1018–76.
2.
BennettW.M., AronoffG.R., MorrisonG.Drug prescribing in renal failure: Dosing guidelines for adults.Am J Kidney Dis1983; 3: 155–93.
3.
SeyffartG.Drugs in renal failure: Dosing guidelines for frequently used drugs in end-stage renal disease and dialysis patients.Blood Purif1985; 3: 140–68.
4.
LasrichM., MaherJ.M., HirszelP., MaherJ.F.Correlation of peritoneal transport rates with molecular weight: A method for predicting clearances.ASAIO J1979; 2: 107–13.
5.
MaherJ.F.Influence of continuous ambulatory peritoneal dialysis on elimination of drugs.Perit Dial Bull1987; 7: 159–67.
6.
HirszelP.Shea-Donohue T, Chakrabarti E, et al. The role of the capillary wall in restricting diffusion of macromolecules.Nephron1988; 49: 58–61.
7.
MaherJ.F., HirszelP., ChakrabartiE., BennettR.R.Contrasting effects of amphotericin B and the solvent, sodium desoxycholate, on peritoneal transport.Nephron1986; 43: 38–42.
8.
EngR.H.K., SmithS.M., BucciniF.Bioavailability of clindamycin during peritoneal dialysis.Chemotherapy1990; 36: 85–90.
9.
BlanchardR., BergerW., BailieG.R., EiseleG.Knowledge of hemodialysis and CAPD patients about their prescribed medicines.Clin Nephrol1990; 34: 173.8.
